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MALIGNANCY is commonly associated
with disorders of haemostasis. Patients
with malignant disease show evidence of
hyper- and hypocoagulable states (Miller
et al., 1967). The latter state may arise
from the former as clotting factors are
consumed, for example by fibrin deposi-
tion around the tumour. O'Meara (1958)
proposed that deposition around tumour
cells is caused by procoagulant activity of
the tumour itselfand provides a matrix on
which the tumour can grow. In addition
to coagulant and fibrinolytic activity,
many human tumour-cell lines promote
platelet aggregation in vitro (Gasic et al.,
1976).
Platelet aggregation is associated with
the release of a number of proteins, in-
cluding a platelet-specific fl-globulin, f-
thromboglobulin (Moore et al., 1975).
Plasma levels of 3-thromboglobulin should
therefore reflect platelet aggregation in
vivo. We report here our findings on :-
thromboglobulin in patients with malig-
nant disease.
/-Thromboglobulin was measured in
platelet-poor plasma by radioimmuno-
assay, using a commercial kit (Radio-
chemical Centre, Amersham). Blood
samples were handled and plasma separ-
ated and stored as recommended by the
manufacturers. Control samples were
taken from hospital staff and patients
without evidence of thromboembolic or
malignant disease.
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Three patients were originally referred
to the Department of Nuclear Medicine
with pulmonary embolism (confirmed by
ventilation-perfusion lung scan). Blood
was taken at the time of scanning for
plasma 3-thromboglobulin determination.
On further investigation these 3 patients
were found to have carcinoma (pancreas,
lung and kidney).
The remaining patients did not-suffer
thromboembolic episodes and had been
referred to the Department of Nuclear
Medicine for bone scanning or to St Luke's
Hospital for radiotherapy and/or chemo-
therapy. Patients were investigated by
conventional clinical, radiological and
radioisotope methods, and were staged
according to the TNM system (IUCC,
1968). Patients with a staging of T4, N3 or
Ml were classed as having advanced
malignancy. In addition to plasma /-
thromboglobulin, the platelet count, pro-
thrombin time and serum fibrinogen/
fibrin degradation products (FDP) were
measured. Of the 23 patients assessed in
this manner, 17 had advanced malignancy
and the remainder had early tumours.
Plasma 3-thromboglobulin levels in
controls and patients with early tumours,
advanced malignancy and malignancy
complicated by pulmonary embolism, are
shown in the Figure. Mean values were,
respectively, 25-8 ng/ml, 26-0 ng/ml, 48.2
ng/ml anld 100 6 ng/ml. Plasma /-thrombo-
globulin levels were significantly raised in
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Table. -Plasma /-thromnboglobulin in
patients with various malignancies
fl-Thromboglobulin
Diagnosis (ng/ml)
Early tumours
Breast 23
P'rostate 27
Larynx 21
Brain (astrocytomna) 48
AMyeloma 18
Lymphoma (non-Hodgkin's) 19
Advanced malignancy
Lung (squamous) 52
Lung (squamous) 10
Lung (undifferentiated large-cell) 54
Lung (oat cell) 69
Lung (oat cell) 57
Breast 63
Breast 12
Breast 45
Breast 98
Kidney (liypeiniiepliroma) 27
Bladder 64
Ovary 62
Laryinx 67
Testis (teratoma) 21
Nasopharynx 32
Antrum .36
AMalignancy with puilmonary embolism
Painereas 150
Lung 82
Kidney (hiypernephroma) 70
CONTROLS EARLY ADVANCED MALIGNANCY
TUMOURS MALIGNANCY + EMBOLISM
FIG. f-Thr)mboglobulin in controls and patient,s
with malignancy.
patients with advanced malignancy when
compared with controls (P < 000 1; Mann-
Whitney U test) and with those with early
tumours (P < 0 025). When malignancy
was complicated by pulmonary embolism,
higher levels of plasma P-thromboglobulin
were found (P < 0.01).
Among the patients with advanced
disease without thromboembolism, 1 had
a low platelet count and 4 had raised
serum FDP levels. None of these findings
was statistically significant (X2 test). No
correlation was found between plasma
/-thromboglobulin and platelet count,
prothrombin time or serum FDP levels.
3-Thromboglobulin has been suggested
as a screening test for deep-vein throm-
bosis (Ludlam et al., 1975). However, it
appears from our findings that patients
with malignant disease would produce a
significant number of false-positive re-
sults. Nevertheless the results in our 3
patients with malignancy and pulmonary
embolism suggest that the effects of
malignancy and venous thromboembolism
on plasma 3-thromboglobulin levels may
be additive, though further studies are
needed to confirm this. It may be that,
following the determination of "baseline"
values for an individual patient, serial
determinations of /-thromboglobulin
could be used to detect thrombotic com-
plications in cancer patients. The effects
of surgery, radiotherapy and chemo-
therapy must first, however, be investi-
gated.
Plasma /-thromboglobulin concentra-
tions appear to correlate inversely with
platelet survival (Doyle et al., 1979).
Patients with advanced malignancy have
shortened platelet survival (Harker &
Slichter, 1972). Our results are not, there-
fore, unexpected. Experimental studies
have shown that platelet aggregation may
occur at several stages of blood-borne
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metastasis (Warren, 1976). Elevated
plasma P-thromboglobulin suggests that
such processes also occur in patients with
malignant disease. Metastasis formation
in animals can be inhibited by induction
of thrombocytopenia or by inhibition of
platelets by aspirin (Gasic et al., 1973).
Should such therapeutic measures be
applied to human cancer, 3-thrombo-
globulin could be used as a marker for
monitoring treatment.
It is not yet certain whether the high
plasma /3-thromboglobulin levels in ad-
vanced malignancy reflect the greater
tumour load or the aggressive nature of
the tumours. Whilst murine tumours with
platelet-aggregating activity have greater
metastatic potential (Gasic et al., 1973),
this has yet to be established for human
tumours. Furthermore a small, localized
tumour may not cause sufficient aggrega-
tion to increase peripheral plasma /-
thromboglobulin levels. Nevertheless the
in vitro studies of Gasic et al. (1976) are
encouraging, and we suggest that platelet
behaviour deserves further investigation
in patients with cancer.
R.J.F. received a Student Research Grant from
the Medical Research Council of Ireland. The work
was presented in preliminary form at the VIIth
International Congress on Thrombosis and Haemo-
stasis, London, July 1979.
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